Influence of Angiotensin Converting Enzyme (ACE) Genotype on Lung Diffusion in Heart Failure

Piergiuseppe Agostoni

Status: Completed

Conditions: Heart Failure, Congestive

Treatments: Drug: isotonic saline infusion

Study type: Interventional

Funder types: Other

Identifiers

NCT00361127

CCM S65/206

Details and patient eligibility

About

In patients with chronic heart failure ACE-inhibitor treatment improves lung diffusion and prevents pulmonary edema after fluid overload. In the western country, 3 population types of ACE genotypes exist (DD, ID, II). It is unknown whether the ACE genotype influences the response to fluid overload in ACE-inhibitor treated chronic heart failure patients.

Full description

Patients with chronic heart failure in stable clinical condition treated with ACE-inhibitors, but not aspirin, will be evaluated by means of maximal cardiopulmonary exercise test and lung function including lung diffusion measurements. These tests will be done before and after rapid 500 ml isotonic saline infusion. Patients will be grouped according to their ACE genotype.

Enrollment: 100 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• New York Heart Association (NYHA) class I and II heart failure
• Chronic ACE-inhibitor treatment

Exclusion criteria

• Aspirin treatment in the previous 2 months

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

CMPD patients

Experimental group

Description:

Patients with CMPD with evaluation of ACE I/D polymorphism

Treatment:

Drug: isotonic saline infusion